Snyder Biomedical — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Snyder Biomedical is pioneering a novel, oral therapeutic approach for neovascular age-related macular degeneration (nAMD) by repurposing L-DOPA to activate the GPR143 receptor. This mechanism aims to naturally downregulate pathologic VEGF in the eye, potentially reducing the treatment burden of frequent intraocular injections. The company has generated promising proof-of-concept clinical data and is advancing toward a Phase 2 prevention trial. Founded by an ophthalmologist and a chemical engineer, Snyder Biomedical holds key intellectual property licensed from the University of Arizona and is seeking a pharmaceutical partner for further development.

OphthalmologyAge-Related Macular Degeneration

Technology Platform

Modulation of the GPR143 receptor on retinal pigment epithelial (RPE) cells using its endogenous ligand L-DOPA to downregulate VEGF secretion at the source, offering an oral, small-molecule approach to treat and prevent neovascular AMD.

Opportunities

The primary opportunity is to disrupt the multi-billion dollar nAMD treatment paradigm by offering an oral therapy that reduces the need for frequent, costly intraocular injections, potentially saving Medicare billions annually.

A secondary, groundbreaking opportunity lies in pioneering the first pharmacologic intervention to prevent the onset of nAMD in the large and growing at-risk population, creating an entirely new market.

Risk Factors

Key risks include the uncertainty of clinical outcomes in larger, controlled trials, particularly for the novel prevention indication.

The company also faces significant competition from entrenched anti-VEGF biologics and next-generation durable therapies, and its advancement is fully dependent on securing a partnership or additional funding as a pre-revenue private entity.

Competitive Landscape

Snyder Biomedical competes in the crowded AMD space dominated by anti-VEGF biologics (Regeneron, Roche/Genentech, Novartis) and newer long-acting formulations (e.g., Susvimo, faricimab). Its key differentiation is the oral small-molecule mechanism targeting VEGF production rather than neutralization. It faces future competition from gene therapies (e.g., RGX-314) aiming for durable VEGF suppression. Its preventive approach, if successful, would have no direct competitors.

More companies in Small Molecule Drugs →More companies in United States →